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http://dx.doi.org/10.1016/j.jmii.2013Purpose: Invasive aspergillosis (IA) is an important cause of morbidity and mortality in immu-
nocompromised patients. Pediatric data on the accuracy and optimal cutoff of galactomannan
antigen detection to diagnose IA is sparse and controversial. We evaluated the utility and
optimal serum galactomannan assay (GA) cutoff in children.
Methods: Children with febrile neutropenia due to malignancy, hematopoietic stem cell trans-
plant, aplastic anemia, or congenital neutropenia, were prospectively included from 2007 to
2011. All new episodes of febrile neutropenia were recorded. In case of a previous diagnosis
of IA, subsequent episodes were excluded. One to four GA were tested by enzyme immuno-
assay during each episode. Bronchoalveolar lavage and other relevant samples for mycological
diagnosis, and computed tomography of chest/sinus were performed wherever appropriate. IA
was classified as “proven”, “probable”, and “possible” as per the 2008 European Organisation
for Research and Treatment of Cancer and Mycoses Study Group Guidelines. The optimal cutoff
value was determined using receiver operating characteristic curves in episode-wise analysis.
Results: There were 145 patients with 211 febrile episodes included: hematopoietic stem cell
transplant (n Z 15), oncological (n Z 113), and hematological disorders (n Z 17). Forty-five
children (31.0%) developed IA (5 proven, 15 probable, and 25 possible). Cutoff value of single
GA  0.7 for proven/probable/possible IA offered the best combination of sensitivity (82.2%)/ematology Oncology and Bone Marrow Transport Unit, Department of Pediatrics, Institute of Child
Delhi 110 060, India.
o.co.in (A. Sachdeva).
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Galactomannan antigenemia in pediatric IA 67specificity (82.5%), and 94.4% negative predictive value. Two consecutive positive GA  0.7 had
a sensitivity/specificity of 75.0%/91.0%. Index GA  1.9 was associated with significantly higher
mortality in children with IA and overall.
Conclusion: Serum GA is sensitive to diagnose IA in pediatric patients with excellent negative
predictive value at an optimal cutoff of 0.7. Considering two consecutive values 0.7 in-
creases specificity to 91.0%.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Invasive fungal infections (IFIs) are a major cause of mor-
tality and morbidity in neutropenic patients after chemo-
therapy for hematological malignancies or hematopoetic
stem cell transplant (HSCT).1 Opportunistic yeasts and
molds are the most prevalent pathogens associated with
IFI.2 The incidence of invasive aspergillosis (IA) has
increased in recent years, particularly among patients
receiving new intensive chemotherapy regimens for malig-
nancies or undergoing allogeneic HSCT.1,3 Despite thera-
peutic advances, IA is associated with high morbidity and
mortality, reaching 30e70% in HSCT recipients.4 Prompt
institution of antifungal therapy is necessary to decrease
mortality, making early diagnosis a critical factor to
improve outcomes in patients with IA. However, early
diagnosis of IA remains difficult, because clinical and
radiological signs are nonspecific, whereas microbiological
culture techniques have a low sensitivity and require
expertise for species identification.1 Although histological
diagnosis by tissue biopsy is the gold standard for IA,5 it is
invasive and may lead to life-threatening complications,
especially among patients with coagulopathy and
thrombocytopenia.
Detection of circulating Aspergillus antigens in the
serum has proven to be a powerful tool for non-invasive
early detection of IA.3,6,7 Galactomannan, a heat stable
heteropolysaccharide cell-wall component of Aspergillus
species, is released into biological fluids during fungal
growth in the tissues.8 Quantitative enzyme immunoassay
(EIA) for serum galactomannan detection is highly sensitive
and superior to polymerase chain reaction (PCR)-based as-
says.9,10 However, the ideal threshold for positive gal-
actomannan assay (GA) remains controversial,11 and may
differ between adults and children, as the latter display
higher false positivity rates. The cutoff optical density (OD)
was initially set at 1.5 and applied in Europe, then lowered
to 0.5 in the USA to allow earlier detection performance for
adult hematology patients.12 Pediatric studies are sparse
and have used various thresholds.
In an effort to standardize the definitions of IFI, an in-
ternational consensus of the Invasive Fungal Infections Co-
operative Group of the European Organisation for Research
and Treatment of Cancer (EORTC) and Mycoses Study Group
(MSG) proposed three levels of probability of IA: “proven”,
“probable”, and “possible”, based on host factors, and
microbiological and clinical criteria.13 GA was included as
mycological criterion in the revised definitions of IA by the
EORTC/MSG, which recommends adopting the threshold
values set by manufacturers.14 However, a systematicreview showed variable accuracy of GA for surveillance and
detection of IA.3
Thus we conducted a prospective study to assess the
utility of GA for diagnosing IA in pediatric patients with
febrile neutropenia and to determine the optimal GA cutoff
value.Methods
Patients with febrile neutropenia younger than 18 years
admitted in the Hematology Oncology Unit, Department of
Pediatrics Sir Ganga Ram Hospital, Rajender Nagar, New
Delhi, India, were included prospectively. Causes of neu-
tropenia included chemotherapy for malignancy, allogenic
or autologous HSCT recipients, aplastic anemia, and
congenital immunodeficiency. Febrile neutropenia was
defined as either a single oral temperature above 38.5C or
an oral temperature of 38C for >1 hour in a child with an
absolute neutrophil count below 1.0  109/L. More than
one treatment episode was included per patient, but once
proven or probable IA was diagnosed, these patients were
no longer eligible for inclusion during subsequent neu-
tropenic episodes.
Demographic and clinical data were recorded. Patients
were tested for the presence of galactomannan antigen if
they met at least one of the following criteria: persisting
neutropenic fever despite administration of 5 days of
broad-spectrum antibiotics, unexplained fever relapsing
after 48 hours of deffervescence while still neutropenic and
on antibiotics, clinical signs or symptoms suggestive of IFI
(lower respiratory tract infection; nasal eschar, maxillary
tenderness, nodular, and/or necrotic skin lesions),
appearance of new pulmonary infiltrate while receiving
broad-spectrum antibiotics or steroids, isolation of molds,
or demonstration of hyphae in respiratory secretions. All
HSCT recipients received antifungal prophylaxis with flu-
conazole (6 mg/kg/day) from the start of pretransplant
conditioning. Positive GA during surveillance of HSCT pa-
tients resulted in a preclinical start of empirical therapy
with either amphotericin B or voriconazole. In case of
clinical suspicion of IFI, empirical antifungal therapy was
started after sampling for GA.
Blood samples (2 mL) were collected in dry tubes for GA.
Paired sera at a minimum of 1 day-interval and follow-up
samples to assess response to antifungal therapy were
evaluated, if possible. High-resolution computed tomogra-
phy (CT) of the chest and sinus was done in patients with
clinical signs or symptoms suggestive of pulmonary or sinus
IFI, and in case of positive GA. Other relevant samples were
68 V. Dinand et al.taken from the study population wherever appropriate
[bronchoalveolar lavage (BAL), endotracheal aspirate, and
biopsy specimens] and were examined for the presence of
fungi by microscopy and culture as previously described.15
IA was classified as “proven”, “probable”, and “possible”
as per EORTC/MSG 2008 Guidelines,12 excluding gal-
actomannan antigen as a mycological criterion.
Serum samples were stored at þ2e8C, for testing
within 24 hours, or kept frozen at 20C otherwise, for a
maximum of 4 days. Twice weekly testing was done.
Quantitative determination of serum Aspergillus gal-
actomannan antigen by one-stage sandwich immunoenzy-
matic technique was done using the Platelia Aspergillus EIA
kit (Bio-Rad, Marnes-la-Coquette, France) as per the man-
ufacturer’s instructions. Positive, negative, and threshold
control samples provided by the manufacturer were
included in each assay. GA was initially considered positive
above an index cutoff OD of 1 and borderline positive at
0.5e1. An experienced laboratory technician trained in EIA
conducted the test and the optical density measurement,
which was then interpreted by two mycologists, unaware of
the patients’ clinical details.
The outcome of all febrile neutropenic episodes was
assessed by clinical response, follow-up GA on antifungal
therapy and 30-day all cause mortality. Statistical analysis
was done on SPSS version 17.0 software (SPSS Inc., Chicago,
IL, USA). Chi-square test was applied to compare categorical
variables. Two-sided p < 0.05 was considered as significant.
Receiver operating characteristic curves were used to
determine the optimal cutoff value in episode-wise analysis,
using the maximum index value obtained during each
episode. The diagnostic value of galactomannan index was
assessed using the area under the curve (95% confidence in-
terval), along with pooled sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)
calculated for proven/probable/possible IA versus no IA
using 2  2 contingency tables with single index value and
two sequential index values above various threshold OD (0.5,
1, 1.5, and optimal threshold value) for GA positivity. Com-
parison of non-normally distributed variables between the
two groups was done using ManneWhitney U test.
Results
Patients
There were 145 patients included prospectively over 5
years (from January 2007 to December 2011) during 211
episodes of febrile neutropenia (Table 1 and Fig. 1). There
were 101 boys and 44 girls, aged from 3 months to 18 years
(median 5 years). Thirty-six patients had high-risk neu-
tropenia after HSCT (n Z 15), intensive chemotherapy for
relapsed, refractory, or high-risk acute lymphoblastic leu-
kemia (n Z 18), and antithymoglobulin therapy (n Z 3),
whereas 109 patients had low-risk neutropenia. Proven,
probable, possible IA, and no evidence of IA were seen in
five children, 15 children, 25 children, and 100 children,
respectively. Forty-five patients with IA were no longer
included during subsequent episodes of febrile neu-
tropenia. IA was pulmonary in 39 patients, sinonasal in
seven individuals, intestinal in one individual, andpericardial and hepatic in one patient. The diagnosis of IA
was based on a combination of positive culture or smear in
20/50 (40.0%) children tested, suggestive CT imaging in 39/
73 (53.4%), and biopsy specimens positive in 5/8 (62.5%).
BAL or endotracheal aspirate was positive in 14 (33.3%) out
of 42 patients. Fungal mold isolates in 16 patients were
Aspergillus flavus (nZ 10), Aspergillus fumigatus (nZ 4),
Fusarium sp. (n Z 2), Mucor sp. (n Z 2), and Conidiobolus
sp. (n Z 1). Positive smear and negative culture were
mostly observed in children receiving antifungal therapy.Galactomannan antigenemia
One to four GA were tested during each febrile episode.
Eleven patients for which only one GA was tested were
excluded from analysis of two consecutive GA. Of 405
serum samples, 134 (33.3%) were above the recommended
positivity cutoff (0.5). Positive GA was observed from 34
days before to 27 days after CT scan suggestive of IA (me-
dian, 3 days) and from 37 days before to 4 days after pos-
itive BAL (median, 3 days). The receiver operating
characteristic curves drawn to assess the value of a single
GA and of two consecutive GA in pooled proven/probable/
possible IA showed that a cutoff value of GA  0.7 offered
the best compromise between increased specificity and
lower sensitivity (Fig. 2).
The GA positivity rate was highest in probable and
proven IA as compared to possible IA (p < 0.001, Table 1).
Out of five proven IA, a false negative result was concurrent
to prior administration of amphotericin B, leading to poorer
performance of GA in the proven IA group than the probable
IA group. Thus sensitivity of a single GA  0.7 and of two
consecutive GA  0.7 was higher in cases with probable IA
than in proven IA and possible IA, whereas specificity was
identical in all three categories. Single GA and two serial
GA  0.7 had a NPV of 94.5% and 92.8% respectively. The
PPVs of single and serial GA  0.7 were 56.1% and 70.2%,
respectively.
During all 211 episodes, 28/45 (62.2%) children with
clinical symptoms suggestive of IA developed proven,
probable, or possible IA, versus 2/19 (10.5%) episodes of
HSCT surveillance and 15/147 (10.2%) with pyrexia of un-
known origin (PUO, p < 0.001). GA positive yield was
significantly higher among children with clinical suspicion
of IA than those with PUO or on routine HSCT surveillance of
GA (p < 0.001). GA was positive for 1e34 days (median, 6
days) prior to the detection of radiological signs in 17/39
(43.6%) patients with chest CT scan suggestive of IA.
False positive single GA  0.7 (n Z 29, 13.7%) was seen
in association with bacterial septic shock (nZ 5), Mucor sp.
induced intestinal perforation (n Z 2), and one case each
of Candida sepsis, gastroenteritis, mucositis, gut graft-
versus-host disease grade IV, piperacillinetazobactam
administration, whereas there was no identifiable cause in
17 cases. Eleven children had only one GA tested, and
either chest CT not suggestive of IFI (nZ 3) or BAL negative
(n Z 2) or neither performed (n Z 6). Follow-up of these
children, who did not receive long-term antifungal therapy,
confirmed the absence of IFI. Seven children had only one
positive GA, the subsequent ones being <0.7.
Table 1 Characteristics of 145 children with febrile neutropenia
Total Proven IA Probable IA Possible IA No IA
Patients n Z 145 n Z 5 n Z 15 n Z 25 n Z 100
Median age, y 5 9 7 8 5
(range) (0.25e19) (3e11) (0.5e19) (2e14) (0.25e16)
Diagnosis
HSCT
Allogenic 9 d 2 d 7
Autologous 6 d d 6
ALL 92 3 7 19 63
AML 14 d 2 3 9
NHL 5 d 2 d 3
Bone marrow failure
Acquired 14 2 1 3 8
Inherited 2 d 1 d 1
SCN 1 d d d 1
Solid tumor 2 d d d 2
Episodes n Z 211 n Z 5 n Z 15 n Z 25 n Z 166
Median index GA 0.1 (0e5.5) 1.9 (0.1e2.4) 2.8 (1.5e5.5) 1.5 (0e4.3) 0.1 (0e4.7)
Single GA
0.5 72 (84.4/79.5) 4 (80/79.5) 15 (100/79.5) 19 (76/79.5) 34
0.7 66 (82.2/82.5) 4 (80/82.5) 15 (100/82.5) 18 (72/82.5) 29
1.0 65 (80.0/82.5) 4 (80/82.5) 15 (100/82.5) 17 (68/82.5) 29
1.5 56 (75.6/86.7) 3 (60/86.7) 15 (100/86.7) 16 (64/86.7) 22
2 consecutive GA n Z 200 n Z 5 n Z 14 n Z 24 n Z 157
0.5 48 (74.4/89.8) 3 (60/89.8) 13 (92.9/89.8) 16 (66.7/89.8) 16
0.7 47 (75.0/91.0) 3 (60/91.0) 14 (93.3/91.0) 16 (66.7/91.0) 14
1.0 43 (69.8/91.7) 3 (60/91.7) 12 (85.7/91.7) 15 (62.5/91.7) 13
1.5 30 (53.5/95.5) 3 (60/95.5) 11 (78.6/95.5) 9 (37.5/95.5) 7
Clinical groups n Z 211 n Z 5 n Z 15 n Z 25 n Z 166
PUO 147 1 5 9 132
HSCT surveillance 19 4 2 d 17
Clinical suspicion of IA 45 8 16 17
Aspergillus sp. in mycological samples n Z 52 n Z 5 n Z 15 n Z 15 n Z 17
Culture þ smear positive 15 4 9 d d
Smear positive 7 1 6 d d
Data are presented as n, n (range), or % (sensitivity/specificity).
ALL Z acute lymphoblastic leukemia; AML Z acute myeloid leukemia; GA Z galactomannan assay; HSCT Z hematopoietic stem cell
transplantation; IAZ invasive aspergillosis; NHLZ non-Hodgkin lymphoma; PUOZ pyrexia of unknown origin; SCNZ severe congenital
neutropenia.
Galactomannan antigenemia in pediatric IA 69When two consecutive GA  0.7 were considered for
positive assay, only 11/200 children (5.5%) had false posi-
tive results. Of these, neither chest CT nor BAL was per-
formed in 3 children. In the rest, chest CT (n Z 7) and BAL
(n Z 2) were negative. One of those children with at least
two consecutive GA  0.7 had sinusal mucosal thickening on
CT scan and no evidence of pulmonary IA during the first
episode, and was classified as having no IA; he developed
possible pulmonary and sinusal IA 10 months later.
We observed 31.6% false positive among HSCT recipients
when single GA  0.7 was used as diagnostic criterion, as
compared to 13.6% in PUO and 6.7% in children with clinical
suspicion of IA (p Z 0.03). However, the use of two serial
GA  0.7 lowered false positive rate to 5.5%: 11.1% among
HSCT recipients, 6.5% in children with PUO and none in
children with clinical suspicion of IA.False negative single GA (<0.7) was seen in four children
on antifungal therapy (amphotericin B or voriconazole, 1
proven IA, and 3 possible IA) and four children without
identifiable cause (all possible IA).Outcome
Response to antifungal therapy was favorable in 31 children
with IA, and GA became <0.7 in 2e54 days (median 8 days)
in those with positive galactomannan antigenemia. The
episode outcomes of 45 patients with IA were survival in 32
cases, death in 11 (24.4%) cases, discharge on request
and loss to follow-up in two cases (Table 2). Causes of
death included invasive fungal infection per se in five
patients, sepsis in five patients and hemophagocytic
211
145 children 
episodes of 
febrile neutropenia
405 serum samples for 
Galactomannan assay
Radiological 
examination           
n = 73
Microbiological 
examination      
n = 42
Histopathological
examination         
n = 8
11 episodes       
Only 1 GA tested, 
excluded from 
analysis of 2 
consecutive GA 
200 episodes
2 GA tested
CT scan 
suggestive of IA  
n = 39
Positive culture 
or smear            
n = 14
Positive 
for IA      
n = 6
Proven IA – 5
Probable IA – 15
Possible IA – 25
No evidence of IA – 100
Figure 1. Flow diagram of 145 patients included in the study and investigations to diagnose invasive aspergillosis (IA).
GA Z galactomannan assay.
70 V. Dinand et al.lymphohistiocytosis with acute hepatic failure in one pa-
tient. Nine (9.0%) children without evidence of IA died (6 of
sepsis, 3 of hemorrhage). Three children discharged on
request and lost to follow-up were excluded from mortality
data. Mortality was significantly higher in children with IA
(proven/probable/possible) than in those with no evidence
of IA. One out of two HSCT recipients with probable IA died.
Aspergillus coinfection with Mucor sp. and with Con-
idiobolus sp. plus Fusarium sp. was seen in two proven IA,
and none survived the episode. Episode-wise mortality rate
was 40% in proven IA, 50% in probable IA, and 8.3% in
possible IA. However, because the probable IA group
included only children with positive cytology or fungal
culture, 18 children with possible IA were later included in
the probable IA group as per the revised definitions of IA,
using GA  0.7 as an indirect mycological criteria, for
correct estimation of mortality in probable IA.14 Thus the
true mortality rate was 29.0% (9/31) in probable IA and 0%
(0/7) in possible IA.
The highest GA index value per episode was compared
between patients with favorable and unfavorable outcome.
Median GA (interquartile range) was significantly higher in
patients with 30-day mortality than in survivors [1.87
(0.11e2.69) vs. 0.09 (0.11e2.69), p < 0.001]. An index
value  1.9 (n Z 31) was significantly associated with
episode mortality in children with IA (42.9% vs. 9.1%,
p Z 0.016) and in the whole cohort (33.3% vs. 5.6%,
p < 0.001). Septic shock and multiorgan failure was seen
more often in children with GA  1.9 (16.1% vs. 3.3%,
p Z 0.012). A high proportion of patients whose serial GA
index values did not decrease below the threshold of 0.7
did not survived the febrile neutropenia episode (41.7% vs.8.3%, p Z 0.059). Children who died had higher GA index
values in the 2nd week and 3rd week of pre-emptive anti-
fungal therapy than those who survived. Conversely,
favorable response to antifungal therapy was associated
with return to a negative GA within 2e54 days (median, 8
days).Discussion
In our children with febrile neutropenia due to HSCT, he-
matological, or oncological disorders, serum EIA gal-
actomannan detection was found to be highly sensitive and
specific for the early detection of IA. Our data suggest that,
in the pediatric age group, a higher positivity threshold
should be chosen than the 0.5 threshold proposed by the
manufacturer. However, the positive predictive value of a
single test was <60% and 70% for two serial GA.
Previous combined adult and pediatric studies showed
that GA specificity is significantly lower in children as in
adults.16 The first European study, including 347 children
and 450 bone marrow transplant patients, considered two
consecutive sera samples 1.5 as criterion for positive
Galactomannan antigen assay, with sensitivity and speci-
ficity of 90.6% and 94%, respectively.17 Two recent studies
were exclusively done in pediatric patients. A single assay
threshold positivity of 0.5 yielded high sensitivity, speci-
ficity, positive, and negative predictive values (90%, 92%,
81.8% and 96%) in 62 febrile neutropenic children with
either leukemia or pancytopenia.18 In that population, ac-
curacy and reliability of GA and nested PCR were compa-
rable. Sensitivity of 91.3% and 81.7% specificity were
Figure 2. Receiver operating characteristic curves for galactomannan assays (GA) in proven/probable/possible invasive asper-
gillosis versus no invasive aspergillosis. AUC 95% confidence interval for a single GA Z 0.788e0.930; for two consecutive
GA Z 0.756e0.927.
Galactomannan antigenemia in pediatric IA 71reported in 99 children with cancer and HSCT recipients,
using two GA  0.5 on two occasions as criteria for
positivity.19
The 2002 EORTC/MSG classification recommended using
two positive results as diagnostic criterion.13 The 2008Table 2 Thirty-day all-cause mortality in 145 children and in 2
Total Died
Patients n Z 145 n Z 2
Group
Proven IA 5 2 (40.0)
Probable IA 15 7 (46.7)
Possible IA 25 2 (8.0)
No IA 100 9 (9.0)
Single highest GA
0.7 62 14 (22.6)
<0.7 83 6 (7.2)
1.9 32 11 (34.4)
<1.9 113 9 (8.0)
Episodes n Z 211 n Z 20
Group
Proven IA 5 2 (40.0)
Probable IA 15 7 (46.7)
Possible IA 25 2 (8.0)
No IA 166 9 (5.4)
Median index GA 0.1 1.9
(IQR) (0.0e1.5) (0.1e2.7)
Single highest GA
0.7 66 14 (21.2)
<0.7 145 6 (4.1)
1.9 31 10 (32.3)
<1.9 180 10 (5.6)
Data are presented as n (%) or n (IQR).
GA Z galactomannan assay; IA Z invasive aspergillosis; IQR Z interqrevised classification no longer makes two positive samples
mandatory.14 In our series, the criterion of two consecutive
values 0.7 yielded lower sensitivity, as repeat GA 2e4
days after initiation of antimold antifungal therapy was
followed by a decrease of GA below the threshold positivity11 febrile neutropenia episodes
Survived p Lost to follow-up
n Z 122 n Z 3
3 (60.0) <0.001 0
7 (46.7) 1 (6.7)
22 (88.0) 1 (4.0)
90 (90.0) 1 (1.0)
46 (74.2) 0.007 2 (3.2)
76 (91.6) 1 (1.2)
19 (59.4) <0.001 2 (1.1)
103 (91.2) 1 (3.2)
n Z 188 p n Z 3
3 (60.0) <0.001 0
7 (46.7) 1 (6.7)
22 (88.0) 1 (4.0)
156 (94.0) 1 (0.6)
0.1 <0.001 1.3
(0.0e1.1) (0.7e1.8)
50 (75.8) <0.001 2 (3.0)
138 (95.2) 1 (0.7)
20 (64.5) <0.001 2 (1.1)
168 (93.3) 1 (3.2)
uartile range.
72 V. Dinand et al.cutoff. However, specificity increased substantially,
particularly among HSCT recipients. Various authors have
shown the benefit of lowering the assay cutoff value from
1.5 to 0.7 or even 0.5 in nonallo-HSCT adults.16 However,
most false-positive results occur in children and in alloge-
neic HSCT patients, with false positive rates of 75% in pe-
diatric HSCT recipients.16,20,21 Although our data include
only 19 episodes of HCST surveillance, false positivity rate
was only 5% using either 1.5 as single GA positivity cutoff or
two serial GA  0.7. Thus GA monitoring appears to be a
good surveillance option for HSCT recipients on prophylac-
tic fluconazole, so as to administer early preemptive anti-
mold therapy.
False positive GA may be caused by the passage of gal-
actomannan of food origin through the intestinal mucosa,
as well as antibiotics such as piperacillinetazobactam.22,23
Out of 29 false positive GA  0.7, we identified intestinal
mucosa damage (e.g. intestinal perforation, gastroenter-
itis, mucositis, and severe gut graft vs. host disease) as
possible causes of false positivity in five children, and
piperacillinetazobactam in one child. In such a clinical
scenario, repeating GA after a few days would reduce the
false positivity rate, thus increasing specificity.
Despite using preemptive antifungal therapy with
amphotericin B or voriconazole, we report high mortality
in proven (40%) and probable IA (29%), similar to previous
pediatric report.19,24 Mortality increased to 100% when
the coinfection of Aspergillus with Mucor sp. and the
coinfection with Conidiobolus sp. plus Fusarium sp. were
seen (2 cases of proven IA). The initial higher mortality
figure in probable IA was inflated by considering as
possible IA 18 children without direct mycological evi-
dence of IA, but with positive indirect mycological crite-
rion. However, a large number of children with possible IA
benefited from preemptive antifungal therapy. We found
that high GA index value ( 1.9) was associated with
septic shock and with significant mortality in our pediatric
population. Higher mortality was also seen wherever
positive GA index did not decrease below threshold posi-
tivity. The use of high GA index value as a potential poor
prognostic marker may be prospectively assessed in larger
studies.
Serum galactomannan antigen monitoring is accurate
and reliable to diagnose invasive aspergillosis in febrile
neutropenic children, with an optimal positivity cutoff of
0.7. Its specificity increases to 91% when two consecutive
values 0.7 are considered. A negative GA practically rules
out IA. A GA value  1.9 is associated with higher risk of
fatal outcome. Prompt return to a negative GA may be a
good indicator of clinical response to antifungal therapy
and predictor of favorable outcome.Conflicts of interest
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